How Ketogenic Diets Target Cancer Cells

By Dr. Lena Suhaila, ND, FABNO

Cancer cells run on a different fuel system than healthy cells. The metabolic gap between them is what makes ketogenic diets matter for cancer biology, and what makes food a tool that can shift the conditions cancer is growing in.

What cancer cells run on

In 1924, German biochemist Otto Warburg observed something unusual. Cancer cells were consuming glucose at rates several times higher than healthy cells, even when oxygen was abundant. Healthy cells, given oxygen, prefer to burn fuel through their mitochondria, an efficient process producing 36 ATP molecules per glucose. Cancer cells, in Warburg’s observations, were skipping the mitochondrial step. They were running glycolysis even when they didn’t have to, producing only 2 ATP per glucose. Less efficient by a wide margin, but they were doing it anyway.

This pattern is now called the Warburg effect, and it’s been documented across most major cancer types. Not all cancers are equally glycolytic. Some are more flexible. But the metabolic shift toward glucose dependency is one of the most consistent features of cancer biology.

Cancer cells often have damaged or dysfunctional mitochondria, which is why the Warburg effect happens. They can’t reliably oxidize fuel through the electron transport chain. So they default to glycolysis, which doesn’t need mitochondrial machinery to produce energy. The cost is efficiency. The benefit, from the cancer cell’s perspective, is that it can keep proliferating in environments where healthy cells can’t.

How a ketogenic diet exploits this

If cancer cells are stuck running on glucose because their mitochondria are damaged, you can use that. You can change the available fuel.

On a high-carbohydrate diet, blood glucose stays in a range that’s plentiful for cancer cells. Insulin stays elevated, and insulin doesn’t just deliver glucose. It activates growth pathways (IGF-1, PI3K, AKT, mTOR) that cancer cells use to multiply. The whole metabolic environment around the tumor is essentially a feeding station.

A ketogenic diet shifts the math. Carbohydrates drop, glucose drops, insulin drops, and the body begins producing ketones, primarily beta-hydroxybutyrate and acetoacetate. These are alternative fuel molecules that healthy cells with functional mitochondria can use efficiently. Cancer cells, with their dysfunctional mitochondria, generally can’t. The glucose-dependent tumor sits in an environment with less of its preferred fuel and a fuel it can’t easily metabolize.

Healthy cells, meanwhile, thrive. The brain runs beautifully on ketones, by some measures even better than on glucose. Muscles use both efficiently. Energy stays steady, inflammation drops, and the signaling pathways that promote cancer growth quiet down because the insulin and IGF-1 driving them have fallen.

The signaling pathways that respond

Insulin and IGF-1 are central. Both bind receptors on cancer cells that activate the PI3K/AKT/mTOR signaling cascade. This is the same cascade that drives proliferation in most ER-positive breast cancers, many colon cancers, glioblastoma, and pancreatic cancers. When insulin and IGF-1 fall (which they do on a ketogenic diet, dramatically and quickly), this cascade quiets.

mTOR is a master regulator of cell growth and proliferation. Cancer cells often have hyperactive mTOR signaling. Pharmaceutical mTOR inhibitors like rapamycin are being studied in oncology. Ketogenic diets suppress mTOR through dietary mechanisms. Not as completely as a drug, but persistently, daily, with no side effects.

The counterweight to mTOR is AMPK, the metabolic stress sensor that gets activated when cellular energy is low. A ketogenic diet, especially when paired with intermittent fasting, activates AMPK. The combination of suppressed mTOR plus activated AMPK creates a cellular environment that favors maintenance and repair over proliferation. Healthy cells handle that fine. Cancer cells, which are addicted to growth signaling, struggle.

What the research shows about mechanism

Systematic reviews of randomized controlled trials show that cancer patients on ketogenic protocols experience reduced fatigue, better sleep quality, lower insulin levels, and improvements in quality of life compared to patients on standard diets. Survival outcome data are still accumulating, but the research already shows something else. The daily experience of living through cancer treatment is measurably better on a ketogenic protocol.

The Khodabakhshi trials out of Iran in 2020 and 2021 looked specifically at breast cancer patients on ketogenic diets alongside chemotherapy. The keto arms showed improvements in metabolic markers, body composition, and tumor response compared to standard-diet arms. A 2020 study from the Osaka group, published in Nutrients, followed advanced cancer patients on a long-term ketogenic regimen. Adherent patients showed encouraging survival outcomes.

No study claims a ketogenic diet cures cancer, and these don’t. What the data show is that the cellular mechanism translates into measurable changes in how cancer behaves and how patients feel.

Where the approach has limits

Mechanism doesn’t equal cure. A ketogenic diet doesn’t make cancer disappear. It changes the environment cancer is operating in, which appears to slow growth and improve treatment response in some cancer types. The diet works best when it’s started carefully, supervised properly, and individualized to the patient’s specific cancer type and treatment status.

Some cancers are less glycolytic and respond less. Patients vary in their ability to tolerate the dietary change. Treatment regimens that require maintaining body weight mean the ketogenic approach has to be calibrated to avoid loss. Supervision matters, and blanket “everyone with cancer should go keto” recommendations are wrong.

For many cancers, the cellular biology is genuinely vulnerable to the metabolic shift a ketogenic diet creates. From Warburg’s original observations to contemporary clinical trials, the mechanism it’s exploiting has nearly a century of research behind it.

If you’re considering a ketogenic approach as part of your cancer care, see my full Ketogenic Diet for Cancer guide for the practical side: who it’s appropriate for, how to start safely, what to test, sample meals, and the protocol I use with patients in clinical practice.

References

1. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-314. https://doi.org/10.1126/science.123.3191.309

2. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029-1033. https://doi.org/10.1126/science.1160809

3. Liberti MV, Locasale JW. The Warburg Effect: How Does it Benefit Cancer Cells? Trends Biochem Sci. 2016;41(3):211-218. https://doi.org/10.1016/j.tibs.2015.12.001

4. Weber DD, Aminzadeh-Gohari S, Tulipan J, Catalano L, Feichtinger RG, Kofler B. Ketogenic diet in the treatment of cancer — Where do we stand? Mol Metab. 2020;33:102-121. https://doi.org/10.1016/j.molmet.2019.06.026

5. Klement RJ, Brehm N, Sweeney RA. Ketogenic diets in medical oncology: a systematic review with focus on clinical outcomes. Med Oncol. 2020;37(2):14. https://doi.org/10.1007/s12032-020-1337-2

6. Khodabakhshi A, Akbari ME, Mirzaei HR, Mehrad-Majd H, Kalamian M, Davoodi SH. Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study. Nutr Cancer. 2020;72(4):627-634. https://doi.org/10.1080/01635581.2019.1650942

7. Khodabakhshi A, Seyfried TN, Kalamian M, Beheshti M, Davoodi SH. Effects of Ketogenic metabolic therapy on patients with breast cancer: A randomized controlled clinical trial. Clin Nutr. 2021;40(3):751-758. https://doi.org/10.1016/j.clnu.2020.06.028

8. Hagihara K, Kajimoto K, Osaka S, et al. Promising Effect of a New Ketogenic Diet Regimen in Patients with Advanced Cancer. Nutrients. 2020;12(5):1473. https://doi.org/10.3390/nu12051473

9. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. Cell. 2017;168(6):960-976. https://doi.org/10.1016/j.cell.2017.02.004

10. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer. 2012;12(3):159-169. https://doi.org/10.1038/nrc3215

11. Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13(4):251-262. https://doi.org/10.1038/nrm3311